Trial Profile
An open-label, multicenter study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Dec 2019
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms JAKVIDA
- 30 Apr 2018 Status changed from recruiting to discontinued.
- 27 Mar 2015 New trial record